Full Text
PUK1 INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) TREATED WITH ANGIOGENESIS INHIBITORS (AIS)

Abstract

Authors

E Dial MS Duh L Antras D Rodermund MP Neary TK Choueiri WK Oh

Back to Volume 13, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×